A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone. Researchers studied anaplastic thyroid cancer cells and tumors in cell culture and in animal models.
Click here to read full press release.Â
###
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.
Mayo Clinic Study Finds Two-drug Combination May Slow Deadly Thyroid Cancer
Mayo Clinic Study Finds Two-drug Combination May Slow Deadly Thyroid Cancer
Mayo Clinic Study Finds Two-drug Combination May Slow Deadly Thyroid Cancer
Mayo Clinic Study Finds Two-drug Combination May Slow Deadly Thyroid Cancer
Mayo Clinic Study Finds Two-drug Combination May Slow Deadly Thyroid Cancer
Source: Health Medicine Network